Chalabi M, Verschoor YL, Tan PB, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 2024;390:1949–1958.

• PubMed
Chalabi M, Verschoor YL, Tan PB, Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 2024;390:1949–1958.)| false
• Search Google Scholar
• Export Citation

Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363–2376.

• PubMed
Cercek A, Lumish M, Sinopoli J, PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363–2376.)| false
• Search Google Scholar
• Export Citation

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386:1973–1985.

• PubMed
Forde PM, Spicer J, Lu S, Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386:1973–1985.)| false
• Search Google Scholar
• Export Citation

Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023;389:491–503.

• PubMed
Wakelee H, Liberman M, Kato T, Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023;389:491–503.)| false
• Search Google Scholar
• Export Citation

Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389:1672–1684.

• PubMed
Heymach JV, Harpole D, Mitsudomi T, Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389:1672–1684.)| false
• Search Google Scholar
• Export Citation

Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386:556–567.

• PubMed
Schmid P, Cortes J, Dent R, Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386:556–567.)| false
• Search Google Scholar
• Export Citation

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813–823.

• PubMed
Patel SP, Othus M, Chen Y, Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813–823.)| false
• Search Google Scholar
• Export Citation

Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022;28:1178–1188.

• PubMed
Reijers ILM, Menzies AM, van Akkooi ACJ, Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022;28:1178–1188.)| false
• Search Google Scholar
• Export Citation

Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023;34:420–430.

• PubMed
Versluis JM, Menzies AM, Sikorska K, Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023;34:420–430.)| false
• Search Google Scholar
• Export Citation

National Cancer Institute. CAR T cells: engineering patients’ immune cells to treat their cancers. Accessed August 12, 2024. Available at: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

• PubMed
National Cancer Institute. CAR T cells: engineering patients’ immune cells to treat their cancers. Accessed August 12, 2024. Available at: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Bispecific antibodies: an area of research and clinical applications. Accessed August 9, 2024. Available at: https://www.fda.gov/drugs/spotlight-cder-science/bispecific-antibodies-area-research-and-clinical-applications

• PubMed
U.S. Food & Drug Administration. Bispecific antibodies: an area of research and clinical applications. Accessed August 9, 2024. Available at: https://www.fda.gov/drugs/spotlight-cder-science/bispecific-antibodies-area-research-and-clinical-applications)| false
• Search Google Scholar
• Export Citation

Fenis A, Demaria O, Gauthier L, et al. New immune cell engagers for cancer immunotherapy. Nat Rev Immunol 2024;24:471–486.

• PubMed
Fenis A, Demaria O, Gauthier L, New immune cell engagers for cancer immunotherapy. Nat Rev Immunol 2024;24:471–486.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Approved cellular and gene therapy products. Accessed August 12, 2024. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

• PubMed
U.S. Food & Drug Administration. Approved cellular and gene therapy products. Accessed August 12, 2024. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products)| false
• Search Google Scholar
• Export Citation

National Library of Medicine. ClinicalTrials.gov. Accessed August 12, 2024. Available at: https://www.clinicaltrials.gov/

• PubMed
National Library of Medicine. ClinicalTrials.gov. Accessed August 12, 2024. Available at: https://www.clinicaltrials.gov/)| false
• Search Google Scholar
• Export Citation

Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38.

• PubMed
Ramos-Casals M, Brahmer JR, Callahan MK, Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38.)| false
• Search Google Scholar
• Export Citation

Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022;19:254–267.

• PubMed
Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022;19:254–267.)| false
• Search Google Scholar
• Export Citation

Apalla Z, Papageorgiou C, Lallas A, et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept 2021;11:e2021155.

• PubMed
Apalla Z, Papageorgiou C, Lallas A, Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept 2021;11:e2021155.)| false
• Search Google Scholar
• Export Citation

Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020;83:1255–1268.

• PubMed
Geisler AN, Phillips GS, Barrios DM, Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020;83:1255–1268.)| false
• Search Google Scholar
• Export Citation

Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015;4:560–575.

• PubMed
Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015;4:560–575.)| false
• Search Google Scholar
• Export Citation

Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016;152:1128–1136.

• PubMed
Shi VJ, Rodic N, Gettinger S, Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016;152:1128–1136.)| false
• Search Google Scholar
• Export Citation

Masterson WM, Brown AM, Al Ameri MA, Patel AB. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. Cancer Treat Res Commun 2022;30:100506.

• PubMed
Masterson WM, Brown AM, Al Ameri MA, Patel AB. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. Cancer Treat Res Commun 2022;30:100506.)| false
• Search Google Scholar
• Export Citation

Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol 2023;14:1071983.

• PubMed
Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol 2023;14:1071983.)| false
• Search Google Scholar
• Export Citation

Brown AM, Masterson W, Lo J, Patel AB. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review. Dermatitis 2023;34:201–208.

• PubMed
Brown AM, Masterson W, Lo J, Patel AB. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review. Dermatitis 2023;34:201–208.)| false
• Search Google Scholar
• Export Citation

Didona D, Caposiena Caro RD, Sequeira Santos AM, et al. Therapeutic strategies for oral lichen planus: state of the art and new insights. Front Med (Lausanne) 2022;9:997190.

• PubMed
Didona D, Caposiena Caro RD, Sequeira Santos AM, Therapeutic strategies for oral lichen planus: state of the art and new insights. Front Med (Lausanne) 2022;9:997190.)| false
• Search Google Scholar
• Export Citation

Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998;134:1521–1530.

• PubMed
Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998;134:1521–1530.)| false
• Search Google Scholar
• Export Citation

Nikolaou V, Sibaud V, Fattore D, et al. Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol 2021;84:1310–1320.

• PubMed
Nikolaou V, Sibaud V, Fattore D, Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol 2021;84:1310–1320.)| false
• Search Google Scholar
• Export Citation

Said JT, Elman SA, Perez-Chada LM, et al. Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review. J Am Acad Dermatol 2022;87:399–400.

• PubMed
Said JT, Elman SA, Perez-Chada LM, Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review. J Am Acad Dermatol 2022;87:399–400.)| false
• Search Google Scholar
• Export Citation

Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020;82:1445–1486.

• PubMed
Menter A, Gelfand JM, Connor C, Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020;82:1445–1486.)| false
• Search Google Scholar
• Export Citation

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029–1072.

• PubMed
Menter A, Strober BE, Kaplan DH, Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029–1072.)| false
• Search Google Scholar
• Export Citation

Vincken NLA, Balak DMW, Knulst AC, et al. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Rheumatology (Oxford) 2022;61:4232–4244.

• PubMed
Vincken NLA, Balak DMW, Knulst AC, Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Rheumatology (Oxford) 2022;61:4232–4244.)| false
• Search Google Scholar
• Export Citation

Srivastava A, Nogueras-Gonzalez GM, Geng Y, et al. Oral toxicities associated with immune checkpoint inhibitors: meta-analyses of clinical trials. J Immunother Precis Oncol 2024;7:24–40.

• PubMed
Srivastava A, Nogueras-Gonzalez GM, Geng Y, Oral toxicities associated with immune checkpoint inhibitors: meta-analyses of clinical trials. J Immunother Precis Oncol 2024;7:24–40.)| false
• Search Google Scholar
• Export Citation

Jacob JS, Dutra BE, Garcia-Rodriguez V, et al. Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer. J Natl Compr Canc Netw 2021;19:1415–1424.

• PubMed
Jacob JS, Dutra BE, Garcia-Rodriguez V, Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer. J Natl Compr Canc Netw 2021;19:1415–1424.)| false
• Search Google Scholar
• Export Citation

Shah N, Cohen L, Seminario-Vidal L. Management of oral reactions from immune checkpoint inhibitor therapy: a systematic review. J Am Acad Dermatol 2020;83:1493–1498.

• PubMed
Shah N, Cohen L, Seminario-Vidal L. Management of oral reactions from immune checkpoint inhibitor therapy: a systematic review. J Am Acad Dermatol 2020;83:1493–1498.)| false
• Search Google Scholar
• Export Citation

Vigarios E, Sibaud V. Oral mucosal toxicities induced by immune checkpoint inhibitors: clinical features and algorithm management. Ann Dermatol Venereol 2023;150:83–88.

• PubMed
Vigarios E, Sibaud V. Oral mucosal toxicities induced by immune checkpoint inhibitors: clinical features and algorithm management. Ann Dermatol Venereol 2023;150:83–88.)| false
• Search Google Scholar
• Export Citation

Warner BM, Baer AN, Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 2019;24:1259–1269.

• PubMed
Warner BM, Baer AN, Lipson EJ, Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 2019;24:1259–1269.)| false
• Search Google Scholar
• Export Citation

Ramos-Casals M, Maria A, Suarez-Almazor ME, et al. Sicca/Sjogren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry. Clin Exp Rheumatol 2019;37(Suppl 118):114–122.

• PubMed
Ramos-Casals M, Maria A, Suarez-Almazor ME, Sicca/Sjogren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry. Clin Exp Rheumatol 2019;37(Suppl 118):114–122.)| false
• Search Google Scholar
• Export Citation

Farag AM, Carey B, Albuquerque R. Oral dysaesthesia: a special focus on aetiopathogenesis, clinical diagnostics and treatment modalities. Br Dent J 2024;236:275–278.

• PubMed
Farag AM, Carey B, Albuquerque R. Oral dysaesthesia: a special focus on aetiopathogenesis, clinical diagnostics and treatment modalities. Br Dent J 2024;236:275–278.)| false
• Search Google Scholar
• Export Citation

Gorsky M, Silverman S Jr, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol 1991;72:192–195.

• PubMed
Gorsky M, Silverman S Jr, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol 1991;72:192–195.)| false
• Search Google Scholar
• Export Citation

Lopez-D’alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011;16:e635–640.

• PubMed
Lopez-D’alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011;16:e635–640.)| false
• Search Google Scholar
• Export Citation

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989;86:10024–10028.

• PubMed
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989;86:10024–10028.)| false
• Search Google Scholar
• Export Citation

June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64–73.

• PubMed
June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64–73.)| false
• Search Google Scholar
• Export Citation

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–638.

• PubMed
Lee DW, Santomasso BD, Locke FL, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625–638.)| false
• Search Google Scholar
• Export Citation

Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 2023;29:438.e1–16.

• PubMed
Hines MR, Knight TE, McNerney KO, Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 2023;29:438.e1–16.)| false
• Search Google Scholar
• Export Citation

Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 2023;142:865–877.

• PubMed
Rejeski K, Subklewe M, Aljurf M, Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 2023;142:865–877.)| false
• Search Google Scholar
• Export Citation

Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract 2022;10:460–466.

• PubMed
Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract 2022;10:460–466.)| false
• Search Google Scholar
• Export Citation

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314–324.

• PubMed
Berdeja JG, Madduri D, Usmani SZ, Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314–324.)| false
• Search Google Scholar
• Export Citation

Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023;41:1265–1274.

• PubMed
Martin T, Usmani SZ, Berdeja JG, Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023;41:1265–1274.)| false
• Search Google Scholar
• Export Citation

Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12:32.

• PubMed
Cohen AD, Parekh S, Santomasso BD, Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 2022;12:32.)| false
• Search Google Scholar
• Export Citation

Karschnia P, Miller KC, Yee AJ, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 2023;142:1243–1248.

• PubMed
Karschnia P, Miller KC, Yee AJ, Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 2023;142:1243–1248.)| false
• Search Google Scholar
• Export Citation

Ciltacabtagene autoleucel suspension for intravenous infusion. Prescribing Information. Janssen Biotech, Inc.; 2024. Accessed August 9, 2024. Available at: https://www.fda.gov/media/156560/download?attachment

• PubMed
Ciltacabtagene autoleucel suspension for intravenous infusion. Prescribing Information. Janssen Biotech, Inc.; 2024. Accessed August 9, 2024. Available at: https://www.fda.gov/media/156560/download?attachment)| false
• Search Google Scholar
• Export Citation

Idecabtagene vicleucel suspension for intravenous infusion. Prescribing Information. Bristol Myers Squibb; 2024. Accessed August 9, 2024. Available at: https://www.fda.gov/media/147055/download?attachment

• PubMed
Idecabtagene vicleucel suspension for intravenous infusion. Prescribing Information. Bristol Myers Squibb; 2024. Accessed August 9, 2024. Available at: https://www.fda.gov/media/147055/download?attachment)| false
• Search Google Scholar
• Export Citation

Graham CE, Lee WH, Wiggin HR, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 2023;142:1248–1252.

• PubMed
Graham CE, Lee WH, Wiggin HR, Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 2023;142:1248–1252.)| false
• Search Google Scholar
• Export Citation

van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barre syndrome. Eur J Neurol 2023;30:3646–3674.

• PubMed
van Doorn PA, Van den Bergh PYK, Hadden RDM, European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barre syndrome. Eur J Neurol 2023;30:3646–3674.)| false
• Search Google Scholar
• Export Citation

Rolin C, Zimmer J, Seguin-Devaux C. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases. Cell Mol Immunol 2024;21:643–661.

• PubMed
Rolin C, Zimmer J, Seguin-Devaux C. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases. Cell Mol Immunol 2024;21:643–661.)| false
• Search Google Scholar
• Export Citation

Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood 2024;143:1565–1575.

• PubMed
Crombie JL, Graff T, Falchi L, Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood 2024;143:1565–1575.)| false
• Search Google Scholar
• Export Citation